ALLAKOS INC (ALLK)

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 123 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company is conducting pre-clinical studies with AK007, which is designed to block known ligand interaction with Siglec-10. The company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Company Info

ALLAKOS INC

825 Industrial Road, Suite 500

San Carlos CALIFORNIA 94065

P: 16505975002

CEO: Robert Alexander

Employees: 123

Website: https://www.allakos.com/